Amiodarone-induced thyrotoxicosis and thyroid cancer: Clinical, immunohistochemical, and molecular genetic studies of a case and review of the literature

Archives of Pathology and Laboratory Medicine

Volumn 128, Issue 7, 2004, Pages 807-810

  Saad, Aly ^a   Falciglia, Mercedes ^b   Steward, David L ^a   Nikiforov, Yuri E ^a  

^a UNIVERSITY OF CINCINNATI COLLEGE OF MEDICINE   (United States)

^b UNIVERSITY OF CINCINNATI   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMIODARONE; CD68 ANTIGEN; DNA; INTERLEUKIN 6; IODINE; LEVOTHYROXINE; LIOTHYRONINE; PROLACTIN; RNA; THIAMAZOLE; THYROGLOBULIN; THYROGLOBULIN ANTIBODY; THYROID HORMONE; THYROID PEROXIDASE; THYROID STIMULATING IMMUNOGLOBULIN; THYROTROPIN; THYROXINE;

ADULT; CASE REPORT; COLOR ULTRASOUND FLOWMETRY; DISEASE ASSOCIATION; HEART ATRIUM FIBRILLATION; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LIVER TOXICITY; MALE; MOLECULAR GENETICS; PHYSICAL EXAMINATION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; REVIEW; THYROID CANCER; THYROID FUNCTION TEST; THYROIDECTOMY; THYROTOXICOSIS;

AMIODARONE; ANTI-ARRHYTHMIA AGENTS; CARCINOMA, PAPILLARY, FOLLICULAR; HUMANS; IMMUNOHISTOCHEMISTRY; MALE; MIDDLE AGED; MUTATION; THYROID NEOPLASMS; THYROTOXICOSIS;

EID: 3042826843     PISSN: 00039985     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (15)

1. Trip MD, Wiersinga W, Plomp TA. Incidence, predictability, and pathogenesis of amiodarone-induced thyrotoxicosis and hypothyroidism. Am J Med. 1991;91:507-511.
2. Harjai KJ, Licata AA. Effects of amiodarone on thyroid function. Ann Intern Med. 1997;126:63-73.
3. Smyrk TC, Goellner JR, Brennan MD, Carney JA. Pathology of the thyroid in amiodarone-associated thyrotoxicosis. Am J Surg Pathol. 1987;11:197-204.
4. Nikiforova MN, Lynch RA, Biddinger PW, et al. RAS point mutations and PAX8-PPAR gamma rearrangement in thyroid tumors: evidence for distinct molecular pathways in thyroid follicular carcinoma. J Clin Endocrinol Metab. 2003;88:2318-2326.
5. Kimura ET, Nikiforova MN, Zhu Z, Knauf JA, Nikiforov YE, Fagin JA. High prevalence of BRAF mutations in thyroid cancer: genetic evidence for constitutive activation of the RET/PTC-RAS-BRAF signaling pathway in papillary thyroid carcinoma. Cancer Res. 2003;63:1454-1457.
6. Nikiforova MN, Caudill CM, Biddinger P, Nikiforov YE. Prevalence of RET/PTC rearrangements in Hashimoto's thyroiditis and papillary thyroid carcinomas. Int J Surg Pathol. 2002;10:15-22.
7. Charlier R, Delaunois G, Bauthier J, Deltour G. Research on the benzofuran series, XL: anti-arrhythmic properties of amiodarone. Cardiology. 1969;54:83-90.
8. Kennedy RL, Griffiths H, Gray TA. Amiodarone and the thyroid. Clin Chem. 1989;35:1882-1887.
9. Sandhu RS, Davies PH. Amiodarone induced thyroid dysfunction: pathophysiology, diagnosis and management. Adverse Drug React Toxicol Rev. 2001;20:105-116.
10. Eaton SE, Euinton HA, Newman CM, Weetman AP, Bennet WM. Clinical experience of amiodarone-induced thyrotoxicosis over a 3-year period: role of colour-flow Doppler sonography. Clin Endocrinol (Oxf). 2002;56:33-38.
11. Casey MB, Lohse CM, Lloyd RV. Distinction between papillary thyroid hyperplasia and papillary thyroid carcinoma by immunohistochemical staining for cytokeratin 19, galectin-3, and HBME-1. Endocr Pathol. 2003;14:55-60.
12. Cheung CC, Ezzat S, Freeman JL, Rosen IB, Asa SL. Immunohistochemical diagnosis of papillary thyroid carcinoma. Mod Pathol. 2001;14:338-342.
13. Mellemgaard A, From G, Jorgensen T, Johansen C, Olsen JH, Perrild H. Cancer risk in individuals with benign thyroid disorders. Thyroid. 1998;8:751-754.
14. Goldman MB, Monson RR, Maloof F. Cancer mortality in women with thyroid disease. Cancer Res. 1990;50:2283-2289.
15. Cattaneo F. Type II amiodarone-induced thyrotoxicosis and concomitant papillary cancer of the thyroid. Eur J Endocrinol. 2000;143:823-824.